SCHEMBL2412873

SCHEMBL2412873

Nc1ccc(Oc2ccnc(-c3cn[nH]c3)c2)c(F)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 1/20 0.45
▸ KDR P35968 1/20 0.41
▸ CHEK1 O14757 3/20 0.39
▸ PIM1 P11309 2/20 0.38
▸ FEN1 P39748 4/20 0.37
▸ ROCK1 Q13464 1/20 0.37
▸ MET P08581 3/20 0.36
▸ ALOX5AP P20292 2/20 0.36
▸ MAPK14 Q16539 1/20 0.36
▸ SCN9A Q15858 2/20 0.35
▸ CSF1R P07333 1/20 0.35
▸ PDGFRB P09619 1/20 0.35
▸ PDGFRA P16234 1/20 0.35
▸ FLT3 P36888 1/20 0.35
▸ CLK2 P49760 1/20 0.35
▸ CLK3 P49761 1/20 0.35
▸ DYRK1A Q13627 1/20 0.35
▸ JAK2 O60674 1/20 0.34
▸ JAK1 P23458 1/20 0.34
▸ TYK2 P29597 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29736704 1.00 AXL (0.45) AXLKDRCHEK1PIM1FEN1
SCHEMBL2030061 0.80 PIM1 (0.40) AXLKDRCHEK1PIM1FEN1
SCHEMBL27762077 0.79 PDE4B (0.40) FEN1ROCK1MAPK14
SCHEMBL29736560 0.78 CSF1R (0.55) AXLKDRMETCSF1RPDGFRB
SCHEMBL2418677 0.78 CSF1R (0.55) AXLKDRMETCSF1RPDGFRB
SCHEMBL29631575 0.76 MET (0.55) AXLKDRFEN1METALOX5AP
SCHEMBL1136810 0.76 MET (0.55) AXLKDRFEN1METALOX5AP
Hydrochloric Acid SCHEMBL1137241 0.74 MET (0.54) AXLKDRFEN1METALOX5AP
SCHEMBL23888712 0.74 MTOR (0.41) KDRCHEK1PIM1FEN1
SCHEMBL30086931 0.74 MTOR (0.41) KDRCHEK1PIM1FEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116283916-B Compound with Axl and c-Met kinase inhibition activity and preparation and application thereof 中国科学院上海药物研究所 2024-06-11 — — CN disclosed
CN-116283916-A Compound with Axl and c-Met kinase inhibition activity and preparation and application thereof 中国科学院上海药物研究所 2023-06-23 — — CN disclosed
CN-112457295-B Compound with Axl and c-Met kinase inhibitory activity and preparation and application thereof 中国科学院上海药物研究所 2022-07-26 — — CN disclosed
WO-2021043217-A1 COMPOUND HAVING AXL AND C-MET KINASE INHIBITORY ACTIVITY, PREPARATION THEREOF AND APPLICATION THEREOF 中国科学院上海药物研究所 2021-03-11 — — WO disclosed
WO-2021043217-A1 COMPOUND HAVING AXL AND C-MET KINASE INHIBITORY ACTIVITY, PREPARATION THEREOF AND APPLICATION THEREOF 中国科学院上海药物研究所 2021-03-11 — — WO disclosed
CN-112457295-A Compound with Axl and c-Met kinase inhibitory activity and preparation and application thereof 中国科学院上海药物研究所 2021-03-09 — — CN disclosed
EP-2365752-B1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS LLC (US) 2014-09-24 — — EP disclosed
US-8486951-B2 Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2013-07-16 — — US disclosed
US-20130079362-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2013-03-28 — — US disclosed
US-8278331-B2 N-acyl ureas exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2012-10-02 — — US disclosed
EP-2365752-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES Deciphera Pharmaceuticals, Llc (US) 2011-09-21 — — EP disclosed
US-20100120806-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC 2010-05-13 — — US disclosed
WO-2010051373-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2010-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079362-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES KIT, PDGFRA, PDGFRB AXL 439/4885KDR 88/4885CHEK1 209/4885
US-20100120806-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES KIT, PDGFRA, PDGFRB AXL 441/4885KDR 89/4885CHEK1 204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback